Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment

Virginia G. Kaklamani, MD, DSc, professor of medicine in the Division of Hematology-Medical Oncology at The University of Texas Health Science Center San Antonio, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen receptor-positive (ER+)/HER2-negative (HER2-) metastatic breast cancer treatment and what community oncologists should know about the ongoing phase 2 ELCIN trial (NCT05596409) evaluating elacestrant in this patient population.

The ELCIN trial is a phase 2 study assessing the efficacy of elacestrant for the treatment of patients aged 18 years and older with ER+/HER2- advanced or metastatic breast cancer who received 1 or 2 prior hormonal therapies and no prior CDK4/6 inhibitors in the metastatic setting.1 Those enrolled in the experimental arm of the trial will recieve a starting dose of elacestrant at 400 mg dihydrochloride administered orally once daily for an estimated 6 months of treatment.

Investiagtors are evaluating the primary end point of progression-free survival. The secondary end points of the trial are overall response rate, duration of response, clinical benefit rate, and overall survival.

Transcription:

0:09 | Based on phase 1 clinical trial data, [elacestrant] is very effective, but this is going to be a larger trial, the ELCIN trial, that will help address that question.

0:19 | It is important that we do trials for our patients, because this is how we come up with new therapies. So, every time you are trying to give a new treatment to a patient, ask yourself, is there a trial available? If there is a trial available, look at the trial and decide if this is a trial that you would want your patient to participate in. But all of these trials are extremely important for our field to move forward, extremely important for us to know exactly how to use elacestrant most effectively.